Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1617SXK

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 4	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 5	MAY 11	KOREAPAT updates resume
NEWS 6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 8	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS 10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS 11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 12	JUl 11	CHEMSAFE reloaded and enhanced
NEWS 13	JUl 14	FSTA enhanced with Japanese patents
NEWS 14	JUl 19	Coverage of Research Disclosure reinstated in DWPI
NEWS 15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 17	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 18	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS 19	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 20	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 21	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 22	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 23	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme

NEWS EXPRESS	JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

```
FILE 'HOME' ENTERED AT 10:52:41 ON 16 OCT 2006

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 10:53:01 ON 16 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 OCT 2006  HIGHEST RN 910448-76-9
DICTIONARY FILE UPDATES:  15 OCT 2006  HIGHEST RN 910448-76-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s TSE-424
           44 TSE
         5529 424
L1          1 TSE-424
                (TSE(W)424)

=> d L1 str cn rn

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
CN   1H-Indol-5-ol, 1-[[4-[2-(hexahydro-1H-azepin-1-yl)ethoxy]phenyl]methyl]-2-
     (4-hydroxyphenyl)-3-methyl-, monoacetate (salt) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   Bazedoxifene acetate
CN   TSE 424
CN   WAY-TES 424
RN   198481-33-3  REGISTRY

     CM   1
```





CM 2



=> s ERA-923
489 ERA
13 ERAS
502 ERA
(ERA OR ERAS)
3046 923
L2 1 ERA-923
(ERA(W)923)

=> d str cn rn L2

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

CN 1H-Indol-5-ol, 2-(4-hydroxyphenyl)-3-methyl-1-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN ERA 923
CN Pipendoxifene
RN 198480-55-6 REGISTRY

```
=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                        24.16      24.37

FILE 'CAPLUS' ENTERED AT 10:55:06 ON 16 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 16 Oct 2006  VOL 145 ISS 17
FILE LAST UPDATED: 15 Oct 2006  (20061015/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 198480-55-6
   REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L4          32 L3

=> dup rem L4
PROCESSING COMPLETED FOR L4
L5          32 DUP REM L4 (0 DUPLICATES REMOVED)

=> s 19848-33-3
L6           0 19848-33-3

=> s L1
L7          44 L1

=> s 19841-33-3
L8           0 19841-33-3

=> s 198481-33-3
   REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.
```

```
L10         44 L9


=> s L4 and (AY<2002 or PRY<2002 or PY<2002)
       4152006 AY<2002
       3594919 PRY<2002
      21842032 PY<2002
L11         20 L4 AND (AY<2002 OR PRY<2002 OR PY<2002)

=> s L10 and (AY<2002 or PRY<2002 or PY<2002)
       4152006 AY<2002
       3594919 PRY<2002
      21842032 PY<2002
L12         23 L10 AND (AY<2002 OR PRY<2002 OR PY<2002)

=> s lactose
          51790 LACTOSE
             94 LACTOSES
L13       51799 LACTOSE
                (LACTOSE OR LACTOSES)

=> s ascorbic acid
          82721 ASCORBIC
        4227204 ACID
        1544534 ACIDS
        4722712 ACID
                (ACID OR ACIDS)
L14       82023 ASCORBIC ACID
                (ASCORBIC(W)ACID)

=> s L11 and L13
L15           6 L11 AND L13

=> s L12 and L13
L16           7 L12 AND L13

=> s L11 and L14
L17           1 L11 AND L14

=> s L12 and L14
L18           1 L12 AND L14

=> d L17 1 ibib abs

L17  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2002:51266  CAPLUS
DOCUMENT NUMBER:          136:107533
TITLE:                    Pharmaceutical compositions containing estrogenic
                          agents
INVENTOR(S):              Benjamin, Eric Joel; Dulin, Wendy Ann; Suryawanshi,
                          Jiwaji Gulabrao
PATENT ASSIGNEE(S):       American Home Products Corporation, USA
SOURCE:                   PCT Int. Appl., 60 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
```

WO 2002003987	A2	20020117	WO 2001-US20993	20010629 <--
WO 2002003987	A3	20020711		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2415058	AA	20020117	CA 2001-2415058	20010629 <--
US 2002031548	A1	20020314	US 2001-896226	20010629 <--
EP 1309327	A2	20030514	EP 2001-950781	20010629 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2001012242	A	20030624	BR 2001-12242	20010629 <--
JP 2004502733	T2	20040129	JP 2002-508441	20010629 <--
NZ 523330	A	20050729	NZ 2001-523330	20010629 <--
NO 2003000030	A	20030303	NO 2003-30	20030103 <--
ZA 2003001004	A	20040505	ZA 2003-1004	20030205 <--
PRIORITY APPLN. INFO.:			US 2000-216192P P	20000706 <--
			WO 2001-US20993 W	20010629 <--

AB This invention comprises novel pharmaceutical carrier or excipient systems and oral pharmaceutical formulations comprising as an active ingredient raloxifene, tamoxifen, droloxifene, arzoxifene, or CP 336156, or analogs, or an indole derivative and the excipients chosen from fillers, glidants, lubricants, wetting agents and antioxidants. Thus, a modified formulation contained micronized TSE-424 acetate 5.00, Lactose NF 41.00, microcryst. cellulose 35.00, pregelatinized starch 10.00, sodium lauryl sulfate 1.50, L-ascorbic acid 1.50, sodium starch glycolate 5.50, Mg stearate 0.50 and water qs to 100%.

=> d L18 1 ibib abs

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2002:51266 CAPLUS
DOCUMENT NUMBER:	136:107533
TITLE:	Pharmaceutical compositions containing estrogenic agents
INVENTOR(S):	Benjamin, Eric Joel; Dulin, Wendy Ann; Suryawanshi, Jiwaji Gulabrao
PATENT ASSIGNEE(S):	American Home Products Corporation, USA
SOURCE:	PCT Int. Appl., 60 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002003987	A2	20020117	WO 2001-US20993	20010629 <--
WO 2002003987	A3	20020711		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,

BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2415058	AA	20020117	CA 2001-2415058	20010629 <--
US 2002031548	A1	20020314	US 2001-896226	20010629 <--
EP 1309327	A2	20030514	EP 2001-950781	20010629 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012242	A	20030624	BR 2001-12242	20010629 <--
JP 2004502733	T2	20040129	JP 2002-508441	20010629 <--
NZ 523330	A	20050729	NZ 2001-523330	20010629 <--
NO 2003000030	A	20030303	NO 2003-30	20030103 <--
ZA 2003001004	A	20040505	ZA 2003-1004	20030205 <--
PRIORITY APPLN. INFO.:			US 2000-216192P P	20000706 <--
			WO 2001-US20993 W	20010629 <--

AB This invention comprises novel pharmaceutical carrier or excipient systems and oral pharmaceutical formulations comprising as an active ingredient raloxifene, tamoxifen, droloxifene, arzoxifene, or CP 336156, or analogs, or an indole derivative and the excipients chosen from fillers, glidants, lubricants, wetting agents and antioxidants. Thus, a modified formulation contained micronized TSE-424 acetate 5.00, Lactose NF 41.00, microcryst. cellulose 35.00, pregelatinized starch 10.00, sodium lauryl sulfate 1.50, L-ascorbic acid 1.50, sodium starch glycolate 5.50, Mg stearate 0.50 and water qs to 100%.

=> s L11 or L12
L19 29 L11 OR L12

=> dup rem L19
PROCESSING COMPLETED FOR L19
L20 29 DUP REM L19 (0 DUPLICATES REMOVED)

=> s L20 and (AY<2001 or PRY<2001 or PY<2001)
L21 29 S L20
3886377 AY<2001
3331401 PRY<2001
20884010 PY<2001
L22 24 L21 AND (AY<2001 OR PRY<2001 OR PY<2001)

=> d 1-24 ibib abs L22

L22 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:142496 CAPLUS
DOCUMENT NUMBER: 136:194234
TITLE: Method using a rapamycin and an antiestrogen for treating estrogen receptor-positive carcinoma
INVENTOR(S): Zhang, Yixian; Sadler, Tammy Michelle; Frost, Philip; Greenberger, Lee Martin
PATENT ASSIGNEE(S): American Home Products Corporation, USA; Wyeth
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002013802	A2	20020221	WO 2001-US24615	20010806 <--
WO 2002013802	A3	20030327		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,

VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2416976	AA	20020221	CA 2001-2416976		20010806 <--
AU 2001083139	A5	20020225	AU 2001-83139		20010806 <--
US 2002045638	A1	20020418	US 2001-923217		20010806 <--
US 6511986	B2	20030128			
EP 1318837	A2	20030618	EP 2001-961914		20010806 <--
EP 1318837	B1	20041006			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004507465	T2	20040311	JP 2002-518948		20010806 <--
AT 278421	E	20041015	AT 2001-961914		20010806 <--
PT 1318837	T	20041231	PT 2001-961914		20010806 <--
ES 2228932	T3	20050416	ES 2001-1961914		20010806 <--
HK 1056687	A1	20050318	HK 2003-109077		20031212 <--
PRIORITY APPLN. INFO.:			US 2000-224326P	P	20000811 <--
			WO 2001-US24615	W	20010806 <--

OTHER SOURCE(S): MARPAT 136:194234

AB The invention provides a method of treating or inhibiting an estrogen receptor-pos. carcinoma in a mammal in need thereof, which comprises providing the mammal with an effective amount of a combination of a rapamycin and an antiestrogen.

L22 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:123193 CAPLUS
DOCUMENT NUMBER: 136:179823
TITLE: Characterization, expression and sequence of human lysyl oxidase EER-7 and use of EER-7 for identifying estrogen receptor ligands
INVENTOR(S): Evans, Mark J.; Scicchitano, Marshall S.; Bapat, Ashok R.; Beer, Eric; Bhat, Ramesh A.; Ferris, Elissa; Mastroeni, Robert; Zhang, Jianziong; Karathanasis, Sotirios K.
PATENT ASSIGNEE(S): American Home Products Corporation, USA; Wyeth
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012470	A2	20020214	WO 2001-US24942	20010808 <--
WO 2002012470	A3	20030828		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2418952	AA	20020214	CA 2001-2418952	20010808 <--
AU 2001084769	A5	20020218	AU 2001-84769	20010808 <--
US 2002102645	A1	20020801	US 2001-924946	20010808 <--
EP 1354046	A2	20031022	EP 2001-963850	20010808 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

BR 2001013257	A	20031028	BR 2001-13257		20010808	<--
JP 2004505631	T2	20040226	JP 2002-517761		20010808	<--
US 2004171110	A1	20040902	US 2003-456982		20030606	<--
PRIORITY APPLN. INFO.:			US 2000-223763P	P	20000808	<--
			US 2000-255838P	P	20001215	<--
			US 2001-924946	A3	20010808	<--
			WO 2001-US24942	W	20010808	<--

AB The present invention relates to a novel human lysyl oxidase termed EER-7. The invention relates to the protein and nucleic acids encoding the protein. The cDNA sequence and the encoded amino acid sequence of EER-7 are disclosed. Expression of EER-7 is regulated by estrogen. The nucleic acid sequence of EER-7 shows homol. to known lysyl oxidase genes. The invention further relates to an assay system to identify compds. that selectively modulate EER-7 protein activity by interaction with estrogen receptors.

L22 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:104615 CAPLUS
DOCUMENT NUMBER: 136:145283
TITLE: Use of an estrogen agonist/antagonist for treating cataracts
INVENTOR(S): Rosati, Robert Louis
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
EP 1177787	A2	20020206	EP 2001-306066		20010713	<--
EP 1177787	A3	20030910				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO						
US 2002016340	A1	20020207	US 2001-915020		20010725	<--
CA 2354208	AA	20020128	CA 2001-2354208		20010726	<--
JP 2002087992	A2	20020327	JP 2001-225530		20010726	<--
ZA 2001006160	A	20030127	ZA 2001-6160		20010726	<--
PRIORITY APPLN. INFO.:			US 2000-221441P	P	20000728	<--

OTHER SOURCE(S): MARPAT 136:145283
AB The invention provides methods, pharmaceutical compns., and kits useful in treating cataracts. The compns. are comprised of an estrogen agonist/antagonist and a pharmaceutically acceptable vehicle, carrier, or diluent. The compns. and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.

L22 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:51431 CAPLUS
DOCUMENT NUMBER: 136:112663
TITLE: Methods and formulations using substituted indole compounds for inhibiting uterotropic effects of estrogenic agents
INVENTOR(S): Jenkins, Simon Nicholas; Komm, Barry Samuel
PATENT ASSIGNEE(S): American Home Products Corporation, USA; Wyeth
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002004418	A2	20020117	WO 2001-US20992	20010629 <--
WO 2002004418	A3	20031106		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002028805	A1	20020307	US 2001-896441	20010629 <--
PRIORITY APPLN. INFO.:			US 2000-216191P P	20000706 <--
OTHER SOURCE(S):	MARPAT 136:112663			

GI



I



II

AB This invention comprises methods and pharmaceutical compns. for minimizing in a mammal the uterotropic effect of a therapeutic compound selected from the group of tamoxifen, droloxifene, raloxifene, idoxifene, centrochroman, levor, meloxifene, TAT-59, GW 5838 or LY-353381, comprising administration of I or II (R1 = H, OH or the C1-C12 esters or C1-C12 alkyl ethers thereof, or halogens; or C1-C4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether; R2, R3, R4, R5, and R6 = H, OH or C1-C12 esters or C1-C12 alkyl ethers thereof, halogens, or C1-C4 halogenated ethers, cyano, C1-C6 alkyl, or trifluoromethyl, with the proviso that, when R1 = H, R2 is not OH; n = 1, 2, or 3; Y = -N(R7)(R8); R7 and R8 = alkyl or concatenated together to form an optionally substituted, nitrogen-containing ring) or a pharmaceutically acceptable salt thereof. When co-dosed with ERA-923, the uterotropic effect of raloxifene was reduced to control values or less at all doses except for 1 μg combined with 10 μg of raloxifene.

L22 ANSWER 5 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2002:51271 CAPLUS
DOCUMENT NUMBER:	136:107535
TITLE:	Therapy for prosthesis-related bone degeneration
INVENTOR(S):	Jenkins, Simon Nicholas; Komm, Barry Samuel; Miller, Christopher Paul
PATENT ASSIGNEE(S):	American Home Products Corporation, USA
SOURCE:	PCT Int. Appl., 41 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002003992	A2	20020117	WO 2001-US21084		20010629 <--
WO 2002003992	A3	20020627			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
US 2002022613	A1	20020221	US 2001-896225		20010629 <--
US 2002028800	A1	20020307	US 2001-896356		20010629 <--
PRIORITY APPLN. INFO.:			US 2000-216406P	P	20000706 <--
			US 2000-216407P	P	20000706 <--

OTHER SOURCE(S): MARPAT 136:107535

AB Methods for treating bone prosthesis degeneration comprise the administration of an indole derivative or its salt, and optionally an estrogen. Thus, a rapid dissoln. formulation contained TSE-424 acetate 10.00, Lactose NF fast flow 33.10, Avicel PH-101 25.00, Starch-1500 20.00, sodium lauryl sulfate 1.50, sodium starch glycolate 10.00, Syloid-244 FP 0.15, and Mg stearate 0,25%.

L22 ANSWER 6 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:51270 CAPLUS
DOCUMENT NUMBER: 136:96098
TITLE: Methods for increasing nitric oxide synthase activity with substituted indole compounds
INVENTOR(S): Adelman, Steven Jay; Argentieri, Thomas Michaell
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002003991	A2	20020117	WO 2001-US21083		20010629 <--
WO 2002003991	A3	20020704			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2414111	AA	20020117	CA 2001-2414111		20010629 <--
US 2002022617	A1	20020221	US 2001-896360		20010629 <--
EP 1296674	A2	20030402	EP 2001-950824		20010629 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2001012360	A	20030506	BR 2001-12360		20010629 <--
JP 2004502734	T2	20040129	JP 2002-508445		20010629 <--
CN 1635885	A	20050706	CN 2001-815092		20010629 <--
PRIORITY APPLN. INFO.:			US 2000-216187P	P	20000706 <--
			WO 2001-US21083	W	20010629 <--

OTHER SOURCE(S): MARPAT 136:96098
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB This invention provides methods of increasing or maintaining mammalian nitric oxide synthase activity and output of nitric oxide comprising administering I or II (R1 = H, OH or the C1-C12 esters of C1-C12 alkyl ethers thereof, or halogens; or C1-C4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether; R2, R3, R4, R5, R6 = H, OH or C1-C12 alkyl ethers thereof, halogens, or C1-C4 halogenated ethers, cyano, C1-C5 alkyl, or trifluoromethyl, with the proviso that, when R1 = H, R2 is not OH; X = H, C1-C6 alkyl, cyano, nitro, trifluoromethyl, halogen; Z = -O(CH2)nY, -CH=CHCOY, -CC(CH2)nY; Y = -N(R7)(R8); n = 1, 2, 3; R7, R8 = alkyl or concatenated together to form an optionally substituted, nitrogen-containing ring) or a pharmaceutically acceptable salt thereof. TSE-424 hydrochloride was tested for its effect on the basal release of NO from the aortic rings of ovariectomized rats. Formulations containing TSE-424 acetate are given.

L22 ANSWER 7 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:51269 CAPLUS
DOCUMENT NUMBER: 136:107534
TITLE: Treatment of excessive intraocular hypertension
INVENTOR(S): Jenkins, Simon Nicholas
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002003990	A2	20020117	WO 2001-US21082	20010629 <--
WO 2002003990	A3	20020912		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002019433	A1	20020214	US 2001-896223	20010629 <--
US 6509332	B2	20030121		

PRIORITY APPLN. INFO.: US 2000-216189P P 20000706 <--
OTHER SOURCE(S): MARPAT 136:107534
AB Methods for the treatment, prevention, inhibition or alleviation of the problems associated with excessive intraocular hypertension comprise the administration of an indole derivative Thus, a rapid dissoln. formulation contained micronized TSE-424 acetate 10.00, Lactose NF fast flow 33.10, Avicel PH-101 25.00, Starch-1500 20.00, sodium lauryl sulfate 1.50, sodium starch glycolate 10.00, Syloid-244 FP 0.15, and Mg stearate 0.25%.

L22 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:51268 CAPLUS
DOCUMENT NUMBER: 136:123638
TITLE: Indole derivatives and estrogens for inhibiting

sphincter incontinence
INVENTOR(S): Jenkins, Simon Nicholas; Argentieri, Thomas Michaell; Miller, Christopher Paul
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002003989	A2	20020117	WO 2001-US21081	20010629 <--
WO 2002003989	A3	20020718		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001071781	A5	20020121	AU 2001-71781	20010629 <--
US 2002019377	A1	20020214	US 2001-896227	20010629 <--
US 6455568	B2	20020924		
US 2002022618	A1	20020221	US 2001-896364	20010629 <--
US 6376486	B2	20020423		
US 2002128305	A1	20020912	US 2002-87248	20020301 <--
US 6635660	B2	20031021		

PRIORITY APPLN. INFO.:
US 2000-216185P P 20000706 <--
US 2000-216186P P 20000706 <--
US 2001-896364 A3 20010629 <--
WO 2001-US21081 W 20010629 <--

OTHER SOURCE(S): MARPAT 136:123638
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB This invention comprises methods of inducing or maintaining sphincter continence, or inhibiting or alleviating incontinence, in a mammal comprising administration of a compound such as I and or a pharmaceutically acceptable salt thereof and optionally an estrogen. A formulation was prepared containing I acetate.

L22 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:51267 CAPLUS
DOCUMENT NUMBER: 136:123637
TITLE: Indole derivatives for treating neuropeptide Y-related conditions
INVENTOR(S): Jenkins, Simon Nicholas
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002003988	A2	20020117	WO 2001-US21048	20010629 <--
WO 2002003988	A3	20020829		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002019392	A1	20020214	US 2001-896362	20010629 <--
US 6358991	B2	20020319		
PRIORITY APPLN. INFO.:			US 2000-216190P P	20000706 <--
OTHER SOURCE(S):	MARPAT 136:123637			

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB This invention comprises methods of treating treatment or prevention of diseases associated with an excess of neuropeptide Y comprising administration of a compound such as I. A formulation was prepared containing I.

L22 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2002:51266 CAPLUS
DOCUMENT NUMBER:	136:107533
TITLE:	Pharmaceutical compositions containing estrogenic agents
INVENTOR(S):	Benjamin, Eric Joel; Dulin, Wendy Ann; Suryawanshi, Jiwaji Gulabrao
PATENT ASSIGNEE(S):	American Home Products Corporation, USA
SOURCE:	PCT Int. Appl., 60 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002003987	A2	20020117	WO 2001-US20993	20010629 <--
WO 2002003987	A3	20020711		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2415058	AA	20020117	CA 2001-2415058	20010629 <--
US 2002031548	A1	20020314	US 2001-896226	20010629 <--
EP 1309327	A2	20030514	EP 2001-950781	20010629 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012242	A	20030624	BR 2001-12242	20010629 <--
JP 2004502733	T2	20040129	JP 2002-508441	20010629 <--
NZ 523330	A	20050729	NZ 2001-523330	20010629 <--

NO 2003000030	A	20030303	NO 2003-30		20030103 <--
ZA 2003001004	A	20040505	ZA 2003-1004		20030205 <--
PRIORITY APPLN. INFO.:			US 2000-216192P	P	20000706 <--
			WO 2001-US20993	W	20010629 <--

AB This invention comprises novel pharmaceutical carrier or excipient systems and oral pharmaceutical formulations comprising as an active ingredient raloxifene, tamoxifen, droloxifene, arzoxifene, or CP 336156, or analogs, or an indole derivative and the excipients chosen from fillers, glidants, lubricants, wetting agents and antioxidants. Thus, a modified formulation contained micronized TSE-424 acetate 5.00, Lactose NF 41.00, microcryst. cellulose 35.00, pregelatinized starch 10.00, sodium lauryl sulfate 1.50, L-ascorbic acid 1.50, sodium starch glycolate 5.50, Mg stearate 0.50 and water qs to 100%.

L22 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:51265 CAPLUS
DOCUMENT NUMBER: 136:123636
TITLE: Indole derivatives for treating breast disorders
INVENTOR(S): Miller, Christopher Paul
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002003986	A2	20020117	WO 2001-US20895	20010629 <--
WO 2002003986	A3	20020808		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002016318	A1	20020207	US 2001-896266	20010629 <--
PRIORITY APPLN. INFO.:			US 2000-216183P	P 20000706 <--
OTHER SOURCE(S):		MARPAT 136:123636		

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB This invention comprises methods of treating treatment of breast disorder comprising administration of a compound such as I. A rapid dissoln. formulation was prepared containing I acetate.

L22 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:51256 CAPLUS
DOCUMENT NUMBER: 136:107532
TITLE: Combinations of statins, estrogenic agents and optionally estrogens
INVENTOR(S): Jenkins, Simon Nicholas; Komm, Barry Samuel; Miller, Christopher Paul
PATENT ASSIGNEE(S): American Home Products Corporation, USA; Wyeth
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 2002003977	A2	20020117	WO 2001-US21085		20010629	<--
WO 2002003977	A3	20030904				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW						
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG						
CA 2414060	AA	20020117	CA 2001-2414060		20010629	<--
US 2002019391	A1	20020214	US 2001-896353		20010629	<--
US 6465454	B2	20021015				
US 2002025952	A1	20020228	US 2001-896632		20010629	<--
BR 2001012365	A	20030513	BR 2001-12365		20010629	<--
EP 1359940	A2	20031112	EP 2001-950826		20010629	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
JP 2004502731	T2	20040129	JP 2002-508432		20010629	<--
PRIORITY APPLN. INFO.:			US 2000-216096P	P	20000706	<--
			US 2000-216184P	P	20000706	<--
			WO 2001-US21085	W	20010629	<--

OTHER SOURCE(S): MARPAT 136:107532

AB This invention comprises methods of treating cardiovascular disorders and lowering blood LDL levels comprising administration of a statin, an estrogen and indole derivs. Thus, a rapid dissoln. formulation contained micronized TSE-424 acetate 10.00, Lactose NF fast flow 33.10, Avicel PH-101 25.00, Starch-1500 20.00, sodium lauryl sulfate 1.50, sodium starch glycolate 10.00, Syloid-244 FP 0.15, and Mg stearate 0.25%.

L22 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:51255 CAPLUS
DOCUMENT NUMBER: 136:107531
TITLE: Combinations of bisphosphonates, estrogenic agents and optionally estrogens
INVENTOR(S): Jenkins, Simon Nicholas; Komm, Barry Samuel; Miller, Christopher Paul
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2002003976	A2	20020117	WO 2001-US20970	20010629	<--
WO 2002003976	A3	20030103			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2415052	AA	20020117	CA 2001-2415052		20010629 <--
US 2002019373	A1	20020214	US 2001-896154		20010629 <--
US 2002028792	A1	20020307	US 2001-896219		20010629 <--
EP 1299093	A2	20030409	EP 2001-952365		20010629 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2001012364	A	20030729	BR 2001-12364		20010629 <--
JP 2004502730	T2	20040129	JP 2002-508431		20010629 <--
PRIORITY APPLN. INFO.:			US 2000-216069P	P	20000706 <--
			US 2000-216188P	P	20000706 <--
			WO 2001-US20970	W	20010629 <--

OTHER SOURCE(S): MARPAT 136:107531

AB Methods of treating bone disorders and lowering blood LDL levels comprise administration of a bisphosphonate, and an indole derivative Thus, a rapid dissoln. formulation contained micronized TSE-424 acetate 10.00, Lactose-NF fast flow 33.10, Avicel-PH 101 25.00, Starch-1500 20.00, sodium lauryl sulfate 1.50, sodium starch glycolate 10.00, Syloid-244 FP 0.15, and Mg stearate 0.25%.

L22 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:51254 CAPLUS
DOCUMENT NUMBER: 136:107530
TITLE: Combinations of serotonin reuptake inhibitor and estrogenic agents
INVENTOR(S): Jenkins, Simon Nicholas
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002003975	A2	20020117	WO 2001-US20738		20010629 <--
WO 2002003975	A3	20020926			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2414938	AA	20020117	CA 2001-2414938		20010629 <--
US 6369051	B2	20020409	US 2001-896361		20010629 <--
US 2002042432	A1	20020411			
EP 1311293	A2	20030521	EP 2001-952310		20010629 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004502729	T2	20040129	JP 2002-508430		20010629 <--
EP 1656938	A1	20060517	EP 2006-1164		20010629 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR					
PRIORITY APPLN. INFO.:			US 2000-216408P	P	20000706 <--
			EP 2001-952310	A3	20010629 <--
			WO 2001-US20738	W	20010629 <--

OTHER SOURCE(S): MARPAT 136:107530

AB Methods of treating depression, anxiety, generalized anxiety disorder

(GAD), hot flash, postpartum depression, premenstrual syndrome, obesity, obsessive compulsive disorder, post-traumatic stress disorder, social phobia, disruptive behavior disorders, impulse control disorders, borderline personality disorder, chronic fatigue disorder, premature ejaculation, pain, attention deficit disorders, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa, or Shy Drager Syndrome comprise administration of a selective serotonin reuptake inhibitor and an indole derivative Thus, a rapid dissoln. formulation contained micronized TSE-424 acetate 10.00, Lactose-NF fast flow 33.10, Avicel-PH 101 25.00, Starch-1500 20.00, sodium lauryl sulfate 1.50, sodium starch glycolate 10.00, Syloid-244 FP 0.15, and Mg stearate 0.25%.

L22 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:876601 CAPLUS
DOCUMENT NUMBER: 136:1102
TITLE: Antiestrogen plus progestin containing oral contraceptives
INVENTOR(S): Gast, Michael J.; Miller, Christopher P.
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: U.S., 11 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 6326392	B1	20011204	US 1998-185058		19981103 <--
US 2002061875	A1	20020523	US 2001-989074		20011121 <--
PRIORITY APPLN. INFO.:			US 1997-93051P	P	19971106 <--
			US 1997-965083	A	19971106 <--
			US 1998-185058	A3	19981103 <--

OTHER SOURCE(S): MARPAT 136:1102
AB A method of providing oral contraception comprises administering to a female of child bearing age a same dosage of a combination of a non-uterotrophic antiestrogen and a progestin for 28 days per 28-day menstrual cycle. For example, a contraceptive kit adapted for daily oral administration comprises 28 sep. dosage units, each containing a combination of 0.5-25 mg 1-[4-(2-azepan-1-yl-ethoxy)benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol acetate and 30-150 μg levonorgestrel.
REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:796237 CAPLUS
DOCUMENT NUMBER: 135:344497
TITLE: Synthesis and use of pyrazolo-pyrimidines as estrogen agonists/antagonists for treating female sexual dysfunction
INVENTOR(S): Lee, Andrew George; Thompson, David Duane; Day, Wesley Warren
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 47 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1149579	A2	20011031	EP 2001-303481	20010412 <--
EP 1149579	A3	20030604		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

US 2002013327	A1	20020131	US 2001-833169	20010411 <--
CA 2344090	AA	20011018	CA 2001-2344090	20010412 <--
JP 2001302547	A2	20011031	JP 2001-117990	20010417 <--
NZ 511131	A	20021126	NZ 2001-511131	20010417 <--
AU 2001038734	A5	20011025	AU 2001-38734	20010418 <--
AU 783165	B2	20050929		
ZA 2001003148	A	20021018	ZA 2001-3148	20010418 <--

PRIORITY APPLN. INFO.: US 2000-266387P P 20000418 <--
OTHER SOURCE(S): MARPAT 135:344497
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = CH2, NR; X, D, E = CH, N; Y = Ph, naphthyl, cycloalk(en)yl, heterocyclyl, etc.; Z1 = alkyl, alkyloxy, alkylamino, etc.; G = amino; R = H, alkyl; n = 0 - 2] were prepared For example, 4-amino-3-ethyl-1H-pyrazole-5-carboxamide was condensed with 3-carboxy-2-ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)pyridine (preparation given, DMF, HOBt, Et3N, EDCI, room temperature, 6 h). The pyrazole moiety of the resulting adduct was N-alkylated (DMF, Cs2CO3, Br(CH2)2OMe, 60°C, 18 h) and cyclized to pyrazolo[4,3-d]pyrimidine II (EtOH, EtOAc, KHMDS, 120°C, 12 h). I are estrogen receptor agonists/antagonists and when co-administered with a cyclic 3',5'-guanosine monophosphate elevator, are used to treat (e.g.) hypoactive sexual desire disorder, sexual arousal disorder, etc.

L22 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:564841 CAPLUS
DOCUMENT NUMBER: 135:132470
TITLE: Selective estrogen receptor modulators in combination with estrogens for therapeutic use
INVENTOR(S): Labrie, Fernand
PATENT ASSIGNEE(S): Endorecherche, Inc., Can.
SOURCE: PCT Int. Appl., 160 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001054699	A1	20010802	WO 2001-CA86	20010126 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2395730	AA	20010802	CA 2001-2395730	20010126 <--
EP 1251855	A1	20021030	EP 2001-902194	20010126 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001008107	A	20030311	BR 2001-8107	20010126 <--
JP 2003520817	T2	20030708	JP 2001-554683	20010126 <--
NZ 534348	A	20060630	NZ 2001-534348	20010126 <--

US 2002198179	A1	20021226	US 2001-52803		20011107 <--
US 2003040510	A1	20030227	US 2001-52824		20011107 <--
US 2003065008	A1	20030403	US 2002-143894		20020509 <--
NO 2002003484	A	20020722	NO 2002-3484		20020722 <--
ZA 2002005926	A	20030724	ZA 2002-5926		20020724 <--
AU 2006201900	A1	20060601	AU 2006-201900		20060505 <--
PRIORITY APPLN. INFO.:			US 2000-178601P	P	20000128 <--
			AU 2001-29913	A3	20010126 <--
			US 2001-771180	A1	20010126 <--
			WO 2001-CA86	W	20010126 <--

OTHER SOURCE(S): MARPAT 135:132470
GI



I

AB Methods for reduction or elimination of the incidence of hot flashes and menopausal symptoms, while decreasing the risk of acquiring breast or endometrial cancer and furthermore treating and/or inhibiting the development of osteoporosis, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, diabetes, loss of muscle mass, obesity, irregular menstruation, Alzheimer's disease, or vaginal dryness in susceptible warm-blooded animals, including humans, involves administration of selective estrogen receptor modulators, particularly compds. I (R1, R2 = OH, moiety convertible to OH in vivo; R3 = (un)saturated (substituted) pyrrolidinyl, (un)saturated (substituted) piperidinyl, etc.) and an amount of an estrogen or mixed estrogenic/androgenic compound Further administration of bisphosphonates, or a sex steroid precursor is specifically disclosed for the medical treatment and/or inhibition of development of some of these above-mentioned diseases. Pharmaceutical compns. for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:559558 CAPLUS
DOCUMENT NUMBER: 135:142234
TITLE: Compositions and methods for treating conditions responsive to estrogen
INVENTOR(S): Thompson, David Duane; Lee, Andrew George; Day, Wesley Warren; Rosati, Robert Louis
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 36 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1120114	A2	20010801	EP 2001-300221	20010111 <--
EP 1120114	A3	20030820		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

ZA 2001000177	A	20020708	ZA 2001-177		20010108	<--
CA 2331053	AA	20010712	CA 2001-2331053		20010110	<--
CA 2331053	C	20051025				
CA 2475393	AA	20010712	CA 2001-2475393		20010110	<--
US 2001041718	A1	20011115	US 2001-758778		20010111	<--
US 6632834	B2	20031014				
NZ 509321	A	20021025	NZ 2001-509321		20010111	<--
AU 780142	B2	20050303	AU 2001-13676		20010111	<--
JP 2001213776	A2	20010807	JP 2001-4452		20010112	<--
US 2004092506	A1	20040513	US 2003-652186		20030829	<--
PRIORITY APPLN. INFO.:			US 2000-175752P	P	20000112	<--
			CA 2001-2331053	A3	20010110	<--
			US 2001-758778	A3	20010111	<--

OTHER SOURCE(S): MARPAT 135:142234

AB This invention relates to methods, pharmaceutical compns. and kits useful in treating conditions responsive to estrogen by the administration of estrogen agonists/antagonists. Conditions responsive to the compns. include rheumatoid arthritis, colon cancer, tissue wounds, skin wrinkles and cataracts. The compns. are comprised of an estrogen agonist/antagonist and a pharmaceutically acceptable vehicle, carrier or diluent. The compns. and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects associated with estrogen administration. The in vitro antiproliferative effects of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol were tested in 2 types of human breast cancer cell lines: first, MCF-7 cells, which contain ER as well as progesterone receptors (PgR), and second, MDA-MB-231 cells, which lack ER and PgR, and enable the determination of an effect that is independent of the ER mechanism. Growth inhibition was ER-specific and not due to cytotoxicity since the compound had no measurable effect on the ER-neg. cell line.

L22 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:283784 CAPLUS
DOCUMENT NUMBER: 134:305328
TITLE: Selective estrogen receptor modulators in the treatment or reduction of the risk of acquiring hypertension, cardiovascular diseases, and insulin resistance
INVENTOR(S): Labrie, Fernand; Marette, Andre
PATENT ASSIGNEE(S): Endorecherche, Inc., Can.
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2001026651	A2	20010419	WO 2000-CA1222	20001013	<--
WO 2001026651	A3	20011108			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-159359P P 19991014 <--
OTHER SOURCE(S): MARPAT 134:305328

GI



I

AB Methods are provided for the medical treatment and/or inhibition of the development of hypertension, cardiovascular diseases, insulin resistance, and diabetes in susceptible warm-blooded animals, including humans, involving administration of a selective estrogen receptor modulator, e.g. EM-652.HCL (I).

L22 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:795633 CAPLUS
DOCUMENT NUMBER: 132:40534
TITLE: Therapeutic uses of a selective estrogen receptor modulator in combination with sex hormone precursors
INVENTOR(S): Labrie, Fernand
PATENT ASSIGNEE(S): Endorecherche, Inc., Can.
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9963974	A2	19991216	WO 1999-CA538	19990610 <--
WO 9963974	A3	20000629		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6465445	B1	20021015	US 1998-96284	19980611 <--
CA 2334577	AA	19991216	CA 1999-2334577	19990610 <--
AU 9942530	A1	19991230	AU 1999-42530	19990610 <--
BR 9911116	A	20010228	BR 1999-11116	19990610 <--
EP 1083905	A2	20010321	EP 1999-955419	19990610 <--
EP 1083905	B1	20051102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
TR 200100551	T2	20010723	TR 2001-200100551	19990610 <--
JP 2002517433	T2	20020618	JP 2000-553043	19990610 <--
TR 200103453	T2	20020621	TR 2001-200103453	19990610 <--
TR 200103454	T2	20020621	TR 2001-200103454	19990610 <--
TR 200103455	T2	20020621	TR 2001-200103455	19990610 <--

TR 200103456	T2	20020621	TR 2001-200103456		19990610 <--
NZ 508801	A	20030829	NZ 1999-508801		19990610 <--
RU 2246947	C2	20050227	RU 2001-101487		19990610 <--
CN 1636566	A	20050713	CN 2004-10097466		19990610 <--
AT 308326	E	20051115	AT 1999-955419		19990610 <--
EP 1623712	A2	20060208	EP 2005-18115		19990610 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY					
ES 2253922	T3	20060601	ES 1999-955419		19990610 <--
US 7005428	B1	20060228	US 1999-405678		19990924 <--
NO 2000006254	A	20010201	NO 2000-6254		20001208 <--
ZA 2000007297	A	20020208	ZA 2000-7297		20001208 <--
AU 2004200099	A1	20040205	AU 2004-200099		20040109 <--
AU 2004200178	A1	20040212	AU 2004-200178		20040116 <--
US 2005137178	A1	20050623	US 2005-62233		20050218 <--
PRIORITY APPLN. INFO.:			US 1998-96284	A	19980611 <--
			AU 1999-42530	A3	19990610 <--
			EP 1999-955419	A3	19990610 <--
			WO 1999-CA538	W	19990610 <--
			US 1999-405678	A3	19990924 <--

OTHER SOURCE(S): MARPAT 132:40534

AB Novel methods for the treatment and/or inhibition of the development of osteoporosis, breast cancer, hypercholesterolemia, hyperlipidemia or atherosclerosis in animals and humans involve administration of selective estrogen receptor modulator such as benzopyran or chroman derivs. and an amount of a sex hormone precursor, e.g., dehydroepiandrosterone, androst-5-ene-3β,17β-diol and compds. converted in vivo to one of the foregoing precursors. Further administration of bisphosphonates in combination with selective estrogen receptor modulators and/or sex hormone precursor is disclosed for the medical treatment and/or inhibition of the development of osteoporosis. Pharmaceutical compns. for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed. Thus, EM-01538 (benzopyran derivative) was prepared in a series of steps starting from resorcinol and 4-hydroxyphenylacetic acid. Capsules contained EM-800 5.0, lactose 80.0, starch 9.8, microcryst. cellulose 9.8, and Mg stearate 0.4%. The effectiveness of the benzopyran derivs. in the treatment of hypercholesterolemia was demonstrated.

L22 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:753069 CAPLUS
DOCUMENT NUMBER: 132:3312
TITLE: 2-Phenyl-1-[4-(2-aminoethoxy)benzyl]indoles for use in combination with estrogens in hormone replacement therapy
INVENTOR(S): Pickar, James Harrison; Komm, Barry Samuel
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9959581	A1	19991125	WO 1999-US10217	19990511 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

US 6479535	B1	20021112	US 1999-306073		19990506 <--
CA 2329530	AA	19991125	CA 1999-2329530		19990511 <--
AU 9938944	A1	19991206	AU 1999-38944		19990511 <--
AU 760378	B2	20030515			
BR 9911040	A	20010213	BR 1999-11040		19990511 <--
EP 1076558	A1	20010221	EP 1999-921834		19990511 <--
EP 1076558	B1	20030716			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
TR 200003377	T2	20010321	TR 2000-200003377		19990511 <--
EE 200000652	A	20020415	EE 2000-652		19990511 <--
EE 4262	B1	20040415			
JP 2002515431	T2	20020528	JP 2000-549246		19990511 <--
AT 245026	E	20030815	AT 1999-921834		19990511 <--
NZ 508200	A	20030926	NZ 1999-508200		19990511 <--
PT 1076558	T	20031128	PT 1999-921834		19990511 <--
ES 2203131	T3	20040401	ES 1999-921834		19990511 <--
SK 284666	B6	20050804	SK 2000-1720		19990511 <--
IL 139130	A1	20051120	IL 1999-139130		19990511 <--
TW 565554	B	20031211	TW 1999-88107747		19990513 <--
NO 2000005770	A	20010112	NO 2000-5770		20001114 <--
HR 2000000778	A1	20010630	HR 2000-778		20001115 <--
HR 20000778	B1	20041031			
ZA 2000006959	A	20011127	ZA 2000-6959		20001127 <--
HK 1031691	A1	20031031	HK 2001-102189		20010326 <--
IN 192220	A	20040320	IN 2001-CA419		20010731 <--
US 2003203883	A1	20031030	US 2002-264187		20021003 <--
US 2006211666	A1	20060921	US 2006-430295		20060508 <--
PRIORITY APPLN. INFO.:			US 1998-109809P	P	19980515 <--
			US 1998-79561	A	19980515 <--
			US 1999-306073	A3	19990506 <--
			WO 1999-US10217	W	19990511 <--
			US 2002-264187	A1	20021003

OTHER SOURCE(S): MARPAT 132:3312

GI



I



II

AB Title compds. (I) [where R1 = H, OH, alkyl ester, alkyl ether, halo, or C1-C4 halogenated ether; R2, R3, R4, R5, and R6 = independently H, OH, alkyl ester, alkyl ether, halo, C1-C4 halogenated ether, CN, alkyl, or CF3; when R1 = H, R2 ≠ OH; X = H, alkyl, CN, NO2, CF3, or halo; n = 2 or 3; Y = (un)substituted amino or (bicyclic) heterocyclyl] were prepared as estrogenic agents for the prevention or treatment of cardiovascular disease, diseases resulting from proliferation or abnormal development, actions or growth of endometrial tissue, or diseases related to estrogen deficiency. Thus, 5-benzyloxy-2-(4-benzyloxyphenyl)-3-Me-1H-indole (preparation given) was treated with NaH followed by addition of Et 4-(chloromethyl)phenoxyacetate to give the N-substituted indole. The acetate was hydrogenated with LiAlH4 and the resulting alc. converted to the bromide by treatment with CBr4. Addition of piperidine followed by deprotection using 10% Pd/C in EtOH yielded II, which showed an IC50 of 0.060 μM against estrogen receptor binding. In a 6-wk ovariectomized rat study, the bone mineral d. of the proximal tibia and fourth lumbar vertebrae, body weight, uterine weight, and cholesterol in female Sprague Dawley CD rats treated with II.HCl were compared with measurements taken of controls and those treated with raloxifene or 17β-estradiol. Estrogen receptor binding data and human estrogen receptor transactivational capacity are reported for approx. 60 invention compds., and the estrogenic and antiestrogenic properties of 11 compds. were determined in an immature rat uterotrophic assay.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:325785 CAPLUS

DOCUMENT NUMBER: 130:347882

TITLE: Oral contraceptives containing antiestrogen and progestin

INVENTOR(S): Gast, Michael Jay; Miller, Christopher Paul

PATENT ASSIGNEE(S): American Home Products Corporation, USA

SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9924027	A2	19990520	WO 1998-US23427	19981104 <--
WO 9924027	A3	19990715		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2307210	AA	19990520	CA 1998-2307210	19981104 <--
AU 9913031	A1	19990531	AU 1999-13031	19981104 <--
AU 760540	B2	20030515		
BR 9813982	A	20000926	BR 1998-13982	19981104 <--
EP 1051179	A2	20001115	EP 1998-956525	19981104 <--
EP 1051179	B1	20050914		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
TR 200001268	T2	20010122	TR 2000-200001268	19981104 <--
EE 200000211	A	20010416	EE 2000-211	19981104 <--

EE 4092	B1	20030815				
JP 2001522798	T2	20011120	JP 2000-520119		19981104	<--
NZ 503890	A	20020828	NZ 1998-503890		19981104	<--
CZ 294155	B6	20041013	CZ 2000-1661		19981104	<--
AT 304359	E	20050915	AT 1998-956525		19981104	<--
ES 2246541	T3	20060216	ES 1998-956525		19981104	<--
ZA 9810136	A	20000505	ZA 1998-10136		19981105	<--
NO 2000002167	A	20000628	NO 2000-2167		20000427	<--
HR 2000000269	A1	20001231	HR 2000-269		20000505	<--
BG 104451	A	20001229	BG 2000-104451		20000517	<--
PRIORITY APPLN. INFO.:			US 1997-965083	A	19971106	<--
			US 1997-66089P	P	19971117	<--
			US 1997-66090P	P	19971117	<--
			US 1997-66095P	P	19971117	<--
			US 1997-66100P	P	19971117	<--
			WO 1998-US23427	W	19981104	<--

OTHER SOURCE(S): MARPAT 130:347882

AB This invention provides a method of providing contraception which comprises administering to a female of child-bearing age a combination of a non-uterotrophic anti-estrogen and a progestin for 28 days/28-day menstrual cycle. When 2-(4-hydroxyphenyl)-3-methyl-1-[4-(2-(azepan-1-yl)ethoxy)benzyl]-1H-indol-5-ol (I) and levonorgestrel are administered according to a 28-day monophasic regimen, the dosage with I at 2 mg and levonorgestrel at 90 μg is preferred.

L22 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:271329 CAPLUS
DOCUMENT NUMBER: 130:296613
TITLE: Preparation of N-[(aryloxy)alkyl]piperidines and analogs as pharmaceutical intermediates
INVENTOR(S): Raveendranath, Panolil; Zeldis, Joseph; Vid, Galina; Potoski, John Richard; Ren, Jianxin
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9919293	A1	19990422	WO 1998-US21609	19981014 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6005102	A	19991221	US 1998-161653	19980928 <--
CA 2306343	AA	19990422	CA 1998-2306343	19981014 <--
AU 9910831	A1	19990503	AU 1999-10831	19981014 <--
AU 757630	B2	20030227		
EP 1025077	A1	20000809	EP 1998-953459	19981014 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9813069	A	20000822	BR 1998-13069	19981014 <--
TR 200001012	T2	20000921	TR 2000-200001012	19981014 <--
EE 200000225	A	20010615	EE 2000-225	19981014 <--
JP 2001519410	T2	20011023	JP 2000-515866	19981014 <--
NZ 503793	A	20021025	NZ 1998-503793	19981014 <--
CN 1765891	A	20060503	CN 2005-10118101	19981014 <--

ZA 9809435	A	20000417	ZA 1998-9435		19981015	<--
US 6242605	B1	20010605	US 1999-458316		19991210	<--
US 6268504	B1	20010731	US 1999-458317		19991210	<--
NO 2000001938	A	20000607	NO 2000-1938		20000413	<--
PRIORITY APPLN. INFO.:			US 1997-90099P	P	19971015	<--
			US 1997-950818	A	19971015	<--
			US 1998-161653	A	19980928	<--
			CN 1998-812149	A3	19981014	<--
			WO 1998-US21609	W	19981014	<--

OTHER SOURCE(S): MARPAT 130:296613

AB R(CR1R2)mZZ1CR1R2R3 [R = NR7R8, heterocyclyl, heteroaryl; R1,R2 = H or (perfluoro)alkyl; R3 = halo, OSO2Me, OSO2CF3, OSO2C6H4R4-4; R4 = halo, NO2, Me, CF3; R7,R8 = H, alkyl, Ph; Z = O or SO0-2; Z1 = (un)substituted phenylene; m = 1-4] were prepared Thus, 4-(HO)C6H4CHO was etherified by 1-(2-chloroethyl)piperidine and the product converted in 2 steps to RCH2CH2OC6H4(CH2Cl)-4 (R = 1-piperidinyl). The latter was employed in preparation of estrogenic 2-(4-hydroxyphenyl)-3-methyl-1-[4-(2-piperidin-1-ylethoxy)benzyl]-1H-indol-5-ol. Data for biol. activity of pharmaceutical agents were given.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:701837 CAPLUS

DOCUMENT NUMBER: 127:358782

TITLE: Preparation of 2-phenyl-1-[4-(2-aminoethoxy)benzyl]indoles as estrogenic agents

INVENTOR(S): Miller, Chris P.; Tran, Bach D.; Collini, Michael D.

PATENT ASSIGNEE(S): American Home Products Corporation, USA

SOURCE: Eur. Pat. Appl., 85 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
EP 802183	A1	19971022	EP 1997-302576	19970415	<--
EP 802183	B1	20011010			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO					
US 5998402	A	19991207	US 1997-833271	19970404	<--
SK 281737	B6	20010710	SK 1997-472	19970415	<--
AT 206701	E	20011015	AT 1997-302576	19970415	<--
ES 2162198	T3	20011216	ES 1997-302576	19970415	<--
PT 802183	T	20020328	PT 1997-302576	19970415	<--
TW 381093	B	20000201	TW 1997-86104919	19970416	<--
AU 9718920	A1	19971023	AU 1997-18920	19970417	<--
AU 710149	B2	19990916			
ZA 9703302	A	19981019	ZA 1997-3302	19970417	<--
CZ 291701	B6	20030514	CZ 1997-1175	19970417	<--
CA 2203079	AA	19971019	CA 1997-2203079	19970418	<--
NO 9701815	A	19971020	NO 1997-1815	19970418	<--
NO 309564	B1	20010219			
CN 1170719	A	19980121	CN 1997-113496	19970418	<--
CN 1106383	B	20030423			
JP 10036346	A2	19980210	JP 1997-101563	19970418	<--
CA 2203078	AA	19981004	CA 1997-2203078	19970418	<--
IL 120701	A1	20050925	IL 1997-120701	19970418	<--
BR 9701895	A	19981110	BR 1997-1895	19970422	<--
HK 1002863	A1	20020215	HK 1998-101958	19980310	<--
US 6127404	A	20001003	US 1999-388580	19990902	<--
US 6326367	B1	20011204	US 1999-388581	19990902	<--

US 6225308	B1	20010501	US 1999-416318		19991012 <--
US 6232307	B1	20010515	US 1999-416078		19991012 <--
US 2001021719	A1	20010913	US 2001-779048		20010208 <--
US 6291451	B2	20010918			
US 2003130274	A1	20030710	US 2002-192069		20020710 <--
US 2004110823	A1	20040610	US 2003-617096		20030710 <--
US 6787538	B2	20040907			
US 2004229932	A1	20041118	US 2003-692777		20031024 <--
US 6951852	B2	20051004			
US 2004110824	A1	20040610	US 2003-720504		20031124 <--
US 6835729	B2	20041228			
US 2005026905	A1	20050203	US 2004-916118		20040811 <--
US 6924281	B2	20050802			
US 2005215616	A1	20050929	US 2005-133113		20050519 <--
US 7041663	B2	20060509			
US 2006094711	A1	20060504	US 2005-302036		20051213 <--
US 2006229296	A1	20061012	US 2006-455302		20060616 <--
PRIORITY APPLN. INFO.:			US 1996-15553P	P	19960419 <--
			US 1996-633974	A	19960419 <--
			US 1997-833271	A	19970404 <--
			US 1999-388581	A3	19990902 <--
			US 1999-416318	A1	19991012 <--
			US 2001-974416	B1	20011010 <--
			US 2002-192069	B1	20020710
			US 2003-617096	A1	20030710
			US 2003-720504	A1	20031124
			US 2004-916118	A1	20040811
			US 2005-133113	A1	20050519
			US 2005-302036	A1	20051213
OTHER SOURCE(S):	MARPAT 127:358782				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I or II; R1 = H, OH, C1-12 ester, etc.; R2-R6 = H, OH, C1-6 alkyl, etc.; X = H, C1-6 alkyl, CN, etc.; n = 2-3; Y = NR7R8 (wherein R7, R8 = H, C1-6 alkyl, (un)substituted Ph; R7R8 = (CH2)p; p = 2-6), 5-7-membered (un)saturated heterocycle, C6-12 bicyclic heterocycle] and their salts, useful as estrogenic agents for treating or preventing bone loss, disease states or syndromes which are caused or associated with an estrogen deficiency, cardiovascular disease, and disease which result from proliferation or abnormal development, actions or growth of endometrial or endometrial-like tissue, were prepared Thus, reaction of 5-benzyloxy-2-(4-benzyloxyphenyl)-1-[4-(2-bromoethoxy)benzyl]-3-methyl-1H-indole with piperidine in THF followed by treatment of the resulting 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1-[4-(2-piperidin-1-ylethoxy)benzyl]-1H-indole with cyclohexadiene in the presence of 10% Pd/C in THF/EtOH afforded the title compound III which showed IC5 of 0.060 nM against estrogen receptor binding.